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Summary
Background: Recurrent glioblastoma multiforme (GBM) is
resistant to most therapeutic endeavors, with low response
rates and survival rarely exceeding six months. There are no
clearly established chemotherapeutic regimens and the aim of
treatment is palliation with improvement in the quality of life.
Patients and methods: We report an open-label, uncontrolled,
multicenter phase II trial of temozolomide in 138 patients
(intent-to-treat [ITT] population) with glioblastoma multiforme
at first relapse and a Karnofsky performance status (KPS)
>70. One hundred twenty-eight patients were histologically
confirmed with GBM or gliosarcoma (GS) by independent
central review. Chemotherapy-naive patients were treated with
temozolomide 200 mg/m2/day orally for the first five days of
a 28-day cycle. Patients previously treated with nitrosourea-
containing adjuvant chemotherapy received 150 mg/m2/day
for the first five days of a 28-day cycle. In the absence of grade
3 or 4 toxicity, patients on the 150 mg/m2 dose schedule were
eligible for a 200 mg/m2 dose on the next cycle.
Results: The primary endpoint was six-month progression-
free survival assessed with strict radiological and clinical crite-
ria. Secondary endpoints included radiological response and
Health-related Quality of Life (HQL). Progression-free survival
at six months was 18% (95% confidence interval (Cl): 11%-
26%) for the eligible-histology population. Median progres-
sion-free survival and median overall survival were 2.1 months
and 5.4 months, respectively. The six-month survival rate was
46%. The objective response rate (complete response and
partial response) determined by independent central review of
gadolinium-enhanced magnetic resonance imaging (MRI)
scans was 8% for both the ITT and eligible-histology popula-
tions, with an additional 43% and 45% of patients, respectively,
having stable disease (SD). Objectively assessed response and
maintenance of a progression-free status were both associated
with HQL benefits (characterized by improvements over base-
line in HQL domains). Temozolomide had an acceptable safety
profile, with only 9% of therapy cycles requiring a dose reduc-
tion due to thrombocytopenia. There was no evidence of
cumulative hematologic toxicity.
Conclusions: Temozolomide demonstrated modest clinical
efficacy, with an acceptable safety profile and measurable
improvement in quality oflife in patients with recurrent GBM.
The use of this drug should be explored further in an adjuvant
setting and in combination with other agents.
Key words: chemotherapy, glioblastoma multiforme, gliosar-
coma, quality oflife, temozolomide, tumor response
Introduction
Glioblastoma multiforme (GBM) is a primary malignant
brain neoplasm characterized by poor differentiation,
with such features as vascular proliferation, necrosis, and
pseudopalisading. Despite aggressive first-line therapy,
consisting of surgery, radiation therapy and adjuvant
chemotherapy, the tumors invariably recur and the
median survival is 9-12 months.
There are no clearly established chemotherapeutic
regimens for the treatment of recurrent GBM. Nitro-
soureas are considered the most effective agents [1],
although there are no reliable comparative data. The
choice of chemotherapeutic regimen for patients who
received previous therapy with nitrosoureas is particu-
larly restricted. Because of cumulative bone marrow
toxicity and the perceived development of chemoresist-
ance, patients relapsing after previous chemotherapy are
often treated with investigational agents. In this setting
chemotherapeutic strategies in patients with recurrent
GBM have used platinum [2-4], procarbazine [5, 6],
tamoxifen [7], and various combinations [8-13]. The
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response rates reported are up to 20%-30% with short
progression-free intervals and a median survival rarely
exceeding six months. Because of these poor results,
chemotherapy for recurrent GBM can only be considered
a palliative treatment. In such a palliative context, inves-
tigational chemotherapeutic agents should be required
to demonstrate functional improvement and enhanced
quality of life with validated Health-related Quality of
Life (HQL) instruments [14, 15].
Temozolomide is a new, orally administered, second
generation imidazotetrazine derivative. It is degraded
spontaneously at physiological pH to the cytotoxic
species 5-(3-methyltriazen-l-yl) imidazole-4-carboxa-
mide (MTIC), and unlike dacarbazine, does not require
hepatic activation [16]. Treatment with temozolomide
results in the formation of N7- and O6-methylguanine,
and O3-methyadenine DNA adducts, although the
O6-methylation product is probably the cytotoxic entity
since tumors that have a high content of the enzyme
O6-methyguanine-DNA-methyl transferase that repair
the lesion tend to be resistant to therapy [17].
The efficacy of temozolomide has been evaluated in
phase I [18], and phase II trials [19-21] in patients with
recurrent malignant glioma In patients with recurrent
anaplastic astrocytoma (AA), temozolomide has also
demonstrated antitumor efficacy, a favorable toxicity
profile, and significant quality of life improvements [22].
We report a single arm phase II study of the palliative
efficacy of temozolomide in patients with recurrent GBM.
Patients and methods
Study design
This multicenter phase II trial was designed to evaluate the antitumor
activity and safety profile of temozolomide in patients with supra-
tentorial GBM at first relapse. Twenty-six international centers partici-
pated in the study. The phase II trial design was similar to that recently
reported for AA at first relapse [22]. Data were compared with those
from an historical database of patients treated with investigative
regimens at the University of California San Francisco. This database
includes 16 phase II trials with protocols similar to that in the current
trial. The primary purpose of this database was to describe the outcome
of 'ineffective' therapies. Agents that provide less than 10% progression-
free survival at six months were deemed "ineffective". Consequently, the
primary endpoint for efficacy chosen in the study was progression-free
survival at six months, estimated from the start of treatment with
temozolomide to the occurrence of disease progression defined as the
onset of tumor regrowth detected on imaging. Based on the initial
review of the historical database, 10% progression-free survival at six
months was chosen as the lower limit of efficacy. A minimum of 100
eligible patients were to be enrolled, so that for a hypothetical pro-
gression-free survival of 20% at 6 months for temozolomide, the 95%
CI would range from 12 2% to 27.8%. The secondary endpoints were
overall survival and objective response rate based on central review
assessment and palliative benefit in terms of improvement in HQL
scores and neurologic function.
Patient eligibility
Patients eligible for enrollment were 18 years of age or older, with
histologically proven supratentorial GBM at first relapse, evidence of
tumor recurrence or progression more than 12 weeks after completion
of radiotherapy, and a KPS > 70. An independent central pathology
review of all histologies was conducted by Dr Janet Bruner, Depart-
ment of Pathology, University of Texas, MD Anderson Cancer Center.
Houston. Texas. Gliomas were classified according to the three-tiered
system of Nelson and Burger [23, 24]. Histologic criteria included the
presence of diffusely infiltrating malignant astrocytoma with necrosis.
In most cases, mitotic activity and microvascular proliferation were
also present. Pseudopahsading necrosis was a required histologic
feature only for those tumors biopsied after radiation therapy. Eligible
histologies included GBM and gliosarcoma (GS) and were based on
the most recent histology prior to enrollment. Patients had to show
unequivocal evidence of first tumor recurrence or progression by
gadolinium (Gd)-enhanced magnetic resonance imaging (MRI) or
contrast-enhanced axial computed tomography (CT) after failing a
conventional course of radiation therapy and not more than one course
of adjuvant nitrosourea-containing chemotherapy. Multifocal disease
was allowed. Required hematologic and chemistry parameters were as
follows: absolute neutrophil count (ANC) ^ 1500/mm3, platelet count
> 100,000/mm3, hemoglobin ^ 10 g/dl or 100 g/1, BUN and serum
creatinine <1.5 times the upper limit of normal (ULN), total and
direct serum bilirubin < 1.5 times the ULN, SGOTor SGPT < 3 times
the ULN, and alkaline phosphatase < 2 times the ULN. Patients were
to have been on a non-increasing dose of steroids for at least 7 days
prior to pretreatment MRI and study start and for at least 72 hours
prior to study drug administration, to have a life expectancy > 12 weeks,
and to have provided written consent.
Treatment
Temozolomide was administered orally, for the first five days of a 28-
day cycle. Chemotherapy-naive patients were given daily doses of 200
mg/m2 temozolomide on therapy days. Patients previously treated with
nitrosourea-containing chemotherapy were started on temozolomide
150 mg/m2 daily on therapy days and were allowed to escalate the dose
to 200 mg/m2 in the next cycle in the absence of any grade 3 or 4
toxicity. Fasting four hours prior to and two hours after administration
was required.
The initiation of a new treatment cycle was based upon strict
hematologic criteria. An ANC and a platelet count ^ 1500/mm3 and
> 100.000/mm3, respectively, were required; otherwise, chemotherapy
was delayed and counts were reassessed weekly for up to four weeks
until these levels were reached. Administration of growth factors to
boost the ANC for the purpose of study drug administration was not
allowed, but rescue with granulocyte colony stimulating factor (G-CSF)
in the case of grade 4 neutropenia was acceptable. Prophylactic
antiemetics were permitted as needed. Only the lowest steroid dose
required to ensure neurologic stability was recommended. Patients
continued treatment for a maximum of one year or until unacceptable
toxicity and/or disease progression occurred.
Patient evaluation
Objective tumor assessment was performed by Gd-enhanced MRI
according to a strictly defined protocol. MRI scanning was performed
at trial entry within two weeks before first chemotherapeutic treatment
and after every second course of chemotherapy. Copies of all scans
were centrally reviewed at Johns Hopkins University. Baltimore,
Maryland, by Dr Nancy Yue. The assessment of tumor response was
based on criteria defined by Macdonald et al. [25] and carried out by
the central reviewer using Gd-enhanced MRI scans in the context of
steroid use, with supporting neurologic evaluation. The assessment of
patients following debulking surgery was confined to those with early
post-surgical MRI where residual nodular masses could be distin-
guished from post-surgical effects.
Neurologic evaluation, which was performed at each study visit, was
based on changes in signs and symptoms from the previous examina-
tion. Relative changes were graded as definitely better (+2). possibly
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Table I. Demographics and characteristics of patients in the intent-to-
treat population.
Parameter Number of patients (%)
Age (years)
Median
Range
Sex
Male
Female
Karnofsky performance status
100
90
80
70
Prior treatment
Prior radiation therapy
Prior chemotherapy
Prior surgery at initial diagnosis
Prior surgery at first relapse
Median time to first relapse (months
(range))
From initial diagnosis
From end of radiation therapy
From surgery at first relapse to study drug
Histologies
Glioblastoma multiforme
Gliosarcoma
Anaplastic astrocytoma
Anaplastic oligoastrocytoma
Low-grade gliomas
Histologies not available
54
24-77
85 (62)
53(38)
7(5)
39 (28)
33 (24)
59 (43)
138(100)
40 (29)
123(89)
18(13)
8.1(1.1-80.2)
5.6 (0.4-75.6)
0.8 (-1.5-23.5)a
126(91)
2(1.5)
3(2)
1(1)
2(1.5)
4(3)
" One patient had surgery 1.5 months after registration.
better (+1), unchanged (0), possibly worse (-1), or definitely worse
(-2).
Adverse events during treatment or up to 30 days after initiation of
therapy were scored according to the NCIC-CTC scale. Abnormal
laboratory values were recorded as serious adverse events only if they
caused hospitalization, transfusion of blood products or discontinua-
tion of therapy.
The impact of therapy on patients'quality of life was assessed with
a self-administered HQL questionnaire. In some instances, however,
proxy completions of HQL forms were assessed. These included the
European Organization for Research and Treatment of Cancer
(EORTC) quality-of-life (QLQ-C30) [14, 26] with 3 additional ques-
tions (hence QLQ-C30 [+3]) and a 20-question brain cancer module
(BCM-20) [15]. Questionnaires were administered on the first day of
the first cycle of therapy and at every visit thereafter. QLQ-C30 scores
were converted to a scale of 0 to 100. A change of ^ 10 was considered
clinically significant and an improvement of > 10 was defined as a
favorable response in HQL domain [27] For the six HQL concepts
related to functioning included in the QLQ-C30, higher values repre-
sent better functioning. For the nine disease-related symptoms com-
monly experienced by patients with cancer and that are included in
the QLQ-C30, higher values represent a greater degree of symptom
severity. For the disease-specific concepts included in BCM-20, higher
scores represent worse disease-related symptoms.
Statistical analyses
The product limit method of Kaplan-Meier was used to estimate the
progression-free survival and event-free survival at six months with a
95% CI. Large sample CIs based on the normal distribution were used
when /; > 30 and the binomial CIs were calculated when n < 30.
All efficacy analyses were carried out on the intent-to-treat (ITT)
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Figure I Kaplan-Meier analysis of time-related efficacy parameters
in patients with GBM at first relapse treated with temozolomide.
population with additional analyses performed on the eligible-histology
population. A Cox regression model was used to assess the potential
influence of baseline characteristics on progression-free survival and
overall survival. Subgroup analyses were based on age, time from
initial diagnosis to first relapse, time from end of radiation treatment
to first relapse and baseline Karnofsky performance status (KPS). Cut-
off points were selected to obtain approximately 50%) of the patients in
each category.
Results
Patient characteristics
From March 22, 1995 to March 25, 1996, 26 interna-
tional centers enrolled 138 patients (ITT population) in
the trial. One hundred twenty-eight patients (93%) had
GBM or GS (eligible-histology population) on central
pathology review. Six of one hundred thirty-eight ITT
patients did not receive temozolomide; therefore, the
safety population included one hundred thirty-two pa-
tients. The characteristics of the ITT population of
patients with GBM and GS eligible for chemotherapy at
first relapse are shown in Table 1. The median age was 54
years. All patients had a KPS over 70. Twenty-nine
percent had received nitrosourea-based adjuvant chemo-
therapy. Most patients (113; 82%) had single lesions,
89% of which were measurable. Tumor size (the product
of two perpendicular diameters) and tumor volume
ranged from < 1 to 60 cm2 and < 1 to 180 cm3, respec-
tively. Eighteen patients (13%) underwent surgery at the
time of relapse. The characteristics of patients in the
eligible histology population were similar.
Therapeutic efficacy
Nineteen percent (95% CI: 12%-26%) and 18% (95%
CI: ll%-24%) of patients, respectively, in the ITT and
eligible-histology populations were progression-free at
six months. The median progression-free survival was
2.1 months. The six-month survival rate was 46% with a
median overall survival 5.4 months (Figure 1). The pro-
gression-free and survival results were identical for each
population.
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Table 2. Prognostic value of various factors on progression-free survival and overall survival by Cox analysis (backward regression method).
Variable Subgroup Patients («) Median PFS
(months)
P-value Median OS
(months)
5.4
5.4
5.4
5.2
5.2
7.2
5.9
5.3
5.4
5.1
7.0
4.4
7.0
5.1
P-v;
NS
0.23
0.21
0.35
0.29
0.04
0.13
Overall
Age
Sex
Prior chemotherapy
Surgery at ID
Time from ID to FR
Baseline KPS
ITT
GBM/GS
>50
<50
Male
Female
Yes
No
Yes
No
> 8 months
< 8 months
>80
S80
138
128
90
48
85
53
40
98
123
15
76
62
46
92
2.1
2.1
2.0
2.8
1.9
2 8
2.1
2.2
2.1
2.1
2.6
1.9
2.4
2.0
NS
0.89
0.14
0.34
0.83
0.03a
0.43
Abbreviations: PFS - progression free survival; OS - overall survival: ID - initial diagnosis: FR - first relapse: RT - radiation therapy; KPS -
Karnofsky performance status.
" Statistically significant.
A Cox regression analysis was performed to identify
prognostic factors for progression-free survival and
overall survival in the ITT population. Time from initial
diagnosis to first relapse was the only independent
predictor of progression-free survival (P = 0.03) and
overall survival (P - 0.04) (Table 2).
As determined by independent central review, objec-
tive response to single agent temozolomide was modest
and similar in each patient population. In the ITT
population, 8% (11 of 138) of patients had either a CR
(2 of 138) or a PR (9 of 138); 60 patients (43%) had
stable disease. In the eligible histology population, 8%
(10 of 128) of patients had either a CR (2 of 128) or a PR
(8 of 128) and 57 patients (45%) had stable disease
(Table 3).
Exposure to temozolomide
The 132 patients treated with temozolomide received a
total of 538 cycles of therapy, 72% of which were admin-
istered at the 200 mg/m2/day dose and 24% at the 150
mg/nr/day dose. The median number of cycles admin-
istered was 3 (range 1 — 14). Seventy-four percent of cycles
were administered on time (^30 days cycle length),
thirteen percent were thirty-one to thirty-five days long,
nine percent were thirty-six to forty-two days long, and
four percent were longer than forty-two days. Only 10%
of cycles were dose reduced.
Adverse events
Adverse events observed in ^ 2% of patients are shown
in Table 4. The most common adverse events were grade
1-2 nausea and vomiting (26% and 24%, respectively)
with few grade 3-4 events (4% in each case). These
values, however, represent emesis without prior pre-
medication, since there was no formal antiemetic policy
in this trial. Administration of conventional antiemetics
Table 3. Objective response rates to temozolomide treatment at first
relapse in patients with glioblastoma multiforme or gliosarcoma (eligi-
ble population) and patients with other brain tumors.
Independently assessed
histology
Independently assessed quality of
response
Complete
response
(CR)
n (%)
Partial
response
(PR)
n (%)
Stable
disease
(SD)
n (%)
GBM/GS (eligible
histology) 2/128(2)
Others 0/10 (0)
Total (ITT population) 2/138(2)
8/128(6) 57/128(45)
1/10 (10) 3/10 (30)
9/138(6) 60/138(43)
upon emesis stopped further vomiting. If 5-HT3 antago-
nists were used preventively, vomiting did not occur.
Grade 3-4 hematologic toxicity occurred in a limited
proportion of patients as thrombocytopenia (10%), leuko-
penia (7%), and neutropenia (4.5%). The toxicity re-
solved with one dose level reduction. Three patients
discontinued treatment due to adverse events.
Quality of life
Of the 138 patients entered in the trial, 12 had no base-
line HQL data and were therefore excluded from the
HQL analysis. Twenty-two patients were eligible for the
HQL analysis as six-month progression-free survivors.
The baseline HQL profiles were similar for patients who
had progressed at six months and for those alive and
progression-free at six months. HQL scores of patients
achieving a response (CR, PR) were compared with
those of the other patients. HQL responses (improve-
ment in score ^ 10) were more common among the 10
CR/PR patients than among those with progressive
disease, with the most improvement recorded in global
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Table 4. Treatment-related adverse events reported in ^ 2% of patients
during all cycles of temozolomide administration.
Adverse events (Aes) Number of patients
(%) (grade 1-2)
Number of patients
(%) (grade 3-4)
Patients with AEs
Thrombocytopenia
Leukopenia
Neutropenia
Anemia
Asthenia
Fatigue
Fever
Headache
Confusion
Convulsions
Dizziness
Hemiparesis
Paresis
Somnolence
Anorexia
Constipation
Diarrhea
Dyspepsia
Stomatitis
Nausea
Vomiting
Alopecia
Petechia
Rash
Oral candidiasis
Pulmonary infection
62 (47)
2(1.5)
1(1)
KD
3(2)
4(3)
16(12)
8(6)
9(7)
2(1.5)
KD
3(2)
1(1)
KD
12(9)
12(9)
6(5)
5(4)
3(2)
3(2)
34 (26)
32(24)
5(4)
10(8)
4(3)
5(4)
2(1 5)
33 (25)
13(10)
9(7)
6(4.5)
2(1 5)
3(2)
3(2)
1(1)
2(1.5)
2(1.5)
2(1.5)
2(1.5)
2(1.5)
KD
5(4)
5(4)
2(1.5)
HQL and motor dysfunction scores (Figure 2). Improve-
ments were also noted in a proportion of patients with
SD and in some progressing patients. Restriction of the
analysis to patients with baseline functioning scores <90
or symptoms scores > 10 (i.e., excluding 21 patients with
normal scores) resulted in a magnification of the HQL
response. Among patients who achieved an objective
clinical response, 75% improved their motor dysfunction
scores, 60% improved their global HQL, and 57% and
20%, respectively, experienced an improvement in com-
munication deficit and visual disorder scores.
Ninety percent of patients achieving an objective
response experienced an HQL response in at least one
domain compared with fifty-eight percent of those with
SD and fifty-two percent of those with PD. The propor-
tion of patients experiencing an HQL response in three
or more HQL domains was also higher in responding
patients than in patients with either SD or PD (Table 5).
The HQL benefit was assessed in the 22 patients
who remained progression-free at 6 months. The mean
changes from baseline in QLQ-C30 (+3) functioning
and symptom scores, and in BCM-20 symptom scores
are shown in Figure 3.
The use of steroids to alleviate symptoms was moni-
tored in order to exclude the potential influence on HQL
independent of chemotherapy. Whereas 30% of HQL
responders did increase concomitant steroid usage dur-
ing the first six months of treatment, at least 60% did
not or even reduced their steroid intake. Five patients in
this latter category discontinued steroid usage entirely.
Discussion
The aim of chemotherapy in patients with recurrent
malignant glioblastoma is to offer a palliative benefit in
terms of improvement in neurologic function and HQL,
or to prevent neurologic deterioration and worsening of
HQL ideally with prolongation of survival. This is
hoped to be achieved by reducing disease burden and
delaying tumor progression.
We evaluated the therapeutic efficacy of single-agent
temozolomide, an oral imidazotetrazine recently intro-
duced for the management of malignant glioma at
recurrence [19, 21, 22, 28, 29]. Patients with GBM at first
relapse were evaluated for response using imaging and
functional indices. The primary endpoints were progres-
sion-free survival and functional/palliative benefits us-
ing a validated instrument of HQL measurement.
The objective response rate according to imaging
data was 8%, and 45% of patients had SD. This repre-
sents an objective assessment based on central radiology
review. Similar results were reported in a previous Can-
cer Research Campaign (CRC) study where the major-
ity of patients had GBM [30]. Although these results
may appear disappointing, there is no published data of
a large homogeneous cohort of patients with GBM
histology alone treated at first recurrence. The published
data usually combines AA and GBM, and the appa-
rently more favorable response rates and survival times
are not applicable to patients with GBM alone, as AA is
associated with higher response rates [1]. In addition,
radiologic endpoints are difficult to assess and are con-
founded by many factors, making conventional response
criteria unreliable [25, 31]. Nevertheless, response rates
in patients with recurrent GBM are low and of short
duration with most patients achieving temporary disease
stabilization.
The primary efficacy end-point in the present study
was defined as six-month progression-free survival. A
review of the literature suggested that an agent demon-
strating a six-month progression-free survival of 10% or
greater would be considered active [32, 33]. However,
reliable data on a selected population of patients with
GBM alone is not available. The six-month progression-
free survival of 18% (95% CI: ll%-26%) in patients with
confirmed GBM is above the limit of 10% set before
the study was initiated and, as such, suggests activity
of temozolomide. The time to progression and median
overall survival of 2.1 months and 5.4 months, respec-
tively, are comparable to results reported in the litera-
ture for various combination regimens. The time from
initial diagnosis to first recurrence/disease progression
was the only independent prognostic factor for progres-
sion-free survival and survival. It suggests that shorter
progression-free interval indicates a biologically more
aggressive disease.
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Table 5. Number of responses in selected QLQ-C30 (+3) functioning domains and BCM20 symptoms domains as a function of clinical response
to temozolomide therapy in patients with malignant glioma.
Clinical response
CR + PR
SD
PD
Total
Number of
patients
10
53
42
105
Number (%) of patients with improved
improved domains)
No improvement
1(10)
22(42)
20(48)
43(41)
Improved in one
or more domains
9(90)
31 (58)
22 (52)
62 (59)
functioning and symptom domains (population
Improved in two Improved in three
or more domains or more domains
8(80)
23(43)
12(29)
43(41)
4(40)
15(28)
7(17)
26(25)
per number of
Improved in four
or more domains
3(30)
9(17)
4(10)
16(15)
Abbreviations. CR - complete response; PR - partial response; SD - stable disease; PD - progressive disease.
Temozolomide has a favorable toxicity profile and
is well tolerated. Grade 4 thrombocytopenia, which
occurred in only 4% of therapy cycles in a limited
number of patients was fully reversible. Grade 3-4
nausea and vomiting were virtually eliminated with
standard antiemetics. By contrast, nitrosoureas cause
delayed and prolonged myelosuppression, which is cu-
mulative [34].
The goal of a palliative treatment is to reduce tumor
burden and improve, or at least prevent, the deterioration
of HQL. The QLQ-C30 (+3) and BCM-20 [14, 15, 26]
used in this trial evaluate a range of domains (global
HQL, physical, role, cognitive, emotional and social
functioning) and disease- and treatment-related signs
and symptoms were selected as appropriate domains for
evaluation in this group of patients. Temozolomide
improved HQL function scores over baseline in patients
who achieved an objective radiologic response and to a
lesser extent in those with SD. This was accomplished
without a concomitant increase in steroid use in the
majority of patients. However, the contribution of ste-
roids to the improvement in HQL scores cannot be ruled
out. The results suggest that radiologic response corre-
lates with clinical/HQL improvement. However, pallia-
tive benefit is seen in a larger proportion of patients than
indicated by radiologic response alone.
In conclusion, temozolomide has modest single-
agent activity in patients with GBM at first relapse. The
favorable safety profile and the efficacy suggest that
temozolomide should be assessed further to optimize its
effectiveness, by exploring its pharmacokinetic profile. It
should also be tested in combination with O6-methyl-
guanine-DNA methyl transferase (AGT) inhibitors and
together with other agents. The ultimate aim should be
to develop an effective regimen that could be tested in
an adjuvant setting. Currently the efficacy of adjuvant
temozolomide is being assessed in multicenter, random-
ized trials of the EORTC and the Radiation Therapy
Oncology Group (RTOG).
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